22:46 , Jun 7, 2019 |  BC Innovations  |  Distillery Therapeutics

Oligoadenylate-conjugated benzimidazole-based miR-210 inhibitor for breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer In vitro and cell culture studies suggest a benzimidazole-based miR-210 inhibitor conjugated to a poly(A) oligonucleotide could help treat triple-negative breast cancer (TNBC). In vitro , a previously reported...
23:18 , Apr 20, 2017 |  BC Innovations  |  Product R&D

Selectivity suite

Although the small molecule landscape has been largely defined by protein-binding agents, new classes of compounds are emerging that block the formation of specific proteins at the level of their RNA, redefining what constitutes a...